PRESS RELEASE Sept. 16, 2020 Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment – Up to 97% reduction in intra-hepatic Z-AAT polymer – Up to 95%...
From the Desk of Miriam O’Day, President & CEO of the Alpha-1 Foundation: “It is with extreme disappointment that the Alpha-1 Foundation received the news that the Takeda Clinical Trial will not proceed forward at this time. The Foundation has every...
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX),...
September 4, 2020 Committee on Equitable Allocation of Vaccine for the Novel Coronavirus; National Academy of Medicine; National Academies of Sciences, Engineering, and Medicine RE: Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19...
Tucked away under the trees at her Shelocta-area home, there’s a special place where Cathy Gould spends her days, writing poetry, reading and reflecting on the life she has now. It’s where she gathers with friends, family and community members. It’s a...
August 18, 2020 The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) has announced the award of a large rare disease grant which will focus on Alpha-1 Antitrypsin Deficiency. The grant entitled Alpha-1 Antitrypsin Disease Cohort:...
